📋 Research Snapshot
Landmark Study: “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial” — Jastreboff et al., New England Journal of Medicine, 2023 (PMID: 37366315)
Key Outcome: 24.2% mean body weight reduction at the highest dose (12mg) over 48 weeks — the highest published Phase II fat loss outcome for any incretin-class compound in clinical research history
Da Nang Context: For expat researchers in Da Nang (Danang) following the frontier of metabolic peptide science, the 2023 NEJM retatrutide publication represents the most significant metabolic research development since tirzepatide’s SURMOUNT-1 results in 2022. Vietnam Peptides’ Da Nang branch provides same-day research access to Retatrutide 20mg.
- 24.2% mean body weight reduction at 12mg weekly over 48 weeks — highest Phase II incretin outcome in published history
- Dose-dependent response confirmed: 8.7% at 1mg, 17.1% at 8mg, 24.2% at 12mg
- Significant improvements in triglycerides (~41% reduction), blood pressure (−7.9 mmHg systolic), and fasting glucose (−20.1 mg/dL)
- Safety profile consistent with GLP-1-class compounds — dose-dependent GI events predominant
- Body composition analysis suggests preferential fat mass reduction vs. lean mass loss
Table of Contents
- Why This Research Matters for Da Nang Expats
- Study Design Overview
- Results Analysis: Body Weight and Composition
- Cardiometabolic Outcomes
- Safety Profile Analysis
- Expert Interpretation: What These Results Mean
- Practical Implications for Danang Research
- Remaining Research Questions
- Key Statistics
- Frequently Asked Questions
- Related Products
- Scientific References
Why This Research Matters for Da Nang Expats
The 2023 New England Journal of Medicine publication on retatrutide (LY3437943) Phase II results represents one of the most significant metabolic research developments in the incretin pharmacology field since tirzepatide’s SURMOUNT-1 data in 2022. For the health-literate expat research community in Da Nang (Danang) — many of whom have followed the GLP-1 research progression from semaglutide through tirzepatide — the retatrutide Phase II data represents the arrival of the next generation: a triple incretin compound with outcomes that surpass anything previously documented in Phase II incretin history.
For Danang expats who research peptides, understand clinical trial data, and make informed decisions about their approach to metabolic health, the 2023 NEJM retatrutide publication is essential reading. This article synthesizes the trial’s key findings, study design, limitations, and implications specifically for the Da Nang expat research context. Vietnam Peptides maintains same-day research access to Retatrutide 20mg from its Danang branch.
Study Design Overview
The Phase II trial (NCT04881760) was a randomized, double-blind, placebo-controlled, parallel-group trial conducted across multiple sites. Three hundred thirty-eight adults with BMI ≥30 kg/m² (or ≥27 with at least one weight-related comorbidity) were enrolled. Participants were randomized to weekly subcutaneous injections of retatrutide at doses of 1mg, 4mg, 8mg, or 12mg, or placebo, for 48 weeks with a 4-week safety follow-up period.
The dose escalation schedule was gradual: participants started at lower doses and escalated every 4 weeks to their target dose. This escalation approach was designed to minimize gastrointestinal side effects during the dose-building phase — the same strategy used successfully in tirzepatide’s SURPASS and SURMOUNT programs. Primary efficacy endpoint was percentage change in body weight from baseline to week 48. Key secondary endpoints included body composition (fat mass vs. lean mass), cardiometabolic markers, and patient-reported outcomes.
Results Analysis: Body Weight and Composition
The primary efficacy results were unequivocal. At 48 weeks, placebo participants achieved −2.1% mean body weight change. Retatrutide arms showed: 1mg: −8.7%; 4mg: −12.9%; 8mg: −17.1%; 12mg: −24.2%. The dose-response relationship was clean and consistent — each dose increment produced meaningful additional weight reduction, with the highest dose producing the most dramatic outcome in Phase II incretin history.
The 12mg dose result of −24.2% is a landmark number. For context: tirzepatide’s SURMOUNT-1 Phase III landmark showed 22.5% at 15mg over 72 weeks; semaglutide’s STEP trials showed approximately 15% at highest dose. Retatrutide’s 24.2% over only 48 weeks in Phase II — with Phase III expected to run longer — positions reta as potentially the highest-efficacy incretin compound yet studied in clinical research.
Body composition sub-studies showed preferential fat mass reduction: approximately 33% of total weight lost was lean mass at the 12mg dose — somewhat higher than ideal but improved relative to historical caloric restriction data. The researchers noted that resistance training was not standardized in the trial population, and future protocols integrating structured exercise may show more favorable lean mass preservation ratios.
💡 Expert Insight
Key Insight: The 24.2% weight reduction in Phase II is not the ceiling — it represents the 48-week outcome at maximum tested dose. Phase III trials (longer duration, refined dose escalation, potentially higher doses) may reveal even greater outcomes over extended treatment periods.
Why It Matters: For Da Nang researchers contextualizing reta’s Phase II data, the 48-week timepoint in SURMOUNT-1 showed approximately 19% for tirzepatide before the 72-week final analysis showed 22.5%. Retatrutide’s Phase III data at 72+ weeks may push beyond the 24.2% Phase II benchmark.
Cardiometabolic Outcomes
Beyond body weight, the 2023 NEJM trial documented comprehensive cardiometabolic improvements at the 12mg dose. Mean fasting blood glucose decreased by −20.1 mg/dL. HbA1c improved by approximately 1.3 percentage points in subgroups with elevated baseline values. Systolic blood pressure declined by a mean of −7.9 mmHg. Triglycerides fell by approximately 41%. HDL cholesterol increased modestly. LDL changes were variable but generally favorable.
These cardiometabolic improvements occurred across the full trial population — not limited to participants with pre-existing metabolic disease. For Da Nang expat researchers interested in comprehensive metabolic health optimization rather than simply body weight reduction, the breadth of cardiometabolic improvement from retatrutide research makes it a multi-dimensional metabolic research tool rather than a narrow fat loss compound.
The mechanism driving these improvements is the multi-receptor architecture: GLP-1 receptor activation improves glycemic control and blood pressure; GIP receptor activation enhances insulin dynamics; glucagon receptor agonism modulates hepatic lipid and glucose metabolism. The convergence of three incretin pathways produces systemic cardiometabolic improvements that no single or dual agonist has achieved to the same degree in Phase II data.
Safety Profile Analysis
The trial’s safety data was consistent with GLP-1-class compound profiles established across previous generations of incretin agents. The most common adverse events were gastrointestinal: nausea (42–62% at higher doses), vomiting (13–27%), diarrhea (14–22%), and decreased appetite. These events were predominantly mild to moderate in severity, occurred most frequently during dose escalation periods, and generally resolved with continued treatment at stable doses.
Serious adverse events were infrequent and distributed comparably between retatrutide and placebo arms at most doses. No significant hepatic toxicity signals, severe cardiovascular events, or unexpected serious adverse events were attributed to retatrutide treatment in the Phase II dataset. The overall safety profile described in the NEJM publication was characterized as consistent with and similar to established GLP-1-class compounds — supporting the compound’s advancement to Phase III investigation.
💡 Expert Insight
Key Insight: The GI side effect profile of retatrutide — while significant — is substantially managed by gradual dose escalation, just as with tirzepatide and semaglutide. The trials that used 4-weekly dose escalation schedules showed meaningfully better tolerability than those with faster escalation.
Why It Matters: For Danang researchers designing reta research protocols, the dose escalation schedule is the most important tolerability variable. Protocols that replicate the trial’s gradual escalation design are expected to produce the most manageable GI side effect profiles based on published data.
Expert Interpretation: What These Results Mean
The 2023 NEJM retatrutide Phase II trial represents a genuine step-change in the incretin pharmacology evidence base. Previous step-changes in this field included: GLP-1 monotherapy (semaglutide achieving 15% weight reduction), dual GIP/GLP-1 agonism (tirzepatide achieving 22.5%), and now triple GIP/GLP-1/glucagon agonism (retatrutide achieving 24.2% in Phase II). Each addition of a receptor target has produced meaningful incremental efficacy — supporting the mechanistic hypothesis that multi-receptor incretin engagement drives additive fat loss biology.
The glucagon receptor component’s contribution to retatrutide’s superior outcomes is strongly suggested by the comparative data, though direct placebo-subtracted attribution studies within the trial design are complex. The thermogenic REE-increasing mechanism of glucagon receptor agonism is mechanistically well-established from preclinical work (Day et al., 2009) and is the most parsimonious explanation for why reta outperforms tirz in head-to-indirect-head comparison.
For Da Nang expat researchers who understand the incretin pharmacology literature, the retatrutide data confirms what the mechanistic hypothesis predicted: adding a thermogenic fat-oxidation pathway (glucagon receptor) to the appetite suppression + adipose tissue signaling framework (GLP-1 + GIP) produces meaningfully superior fat loss outcomes. The Phase III data will determine whether this advantage holds at population scale and extended duration.
Practical Implications for Danang Research
For Da Nang expat researchers following the retatrutide literature, the Phase II publication’s practical implications are direct. The 48-week timeframe of the Phase II trial aligns with realistic research protocol durations. The dose-response relationship suggests starting at lower doses (consistent with the clinical trial escalation design) and titrating based on response and tolerability. The cardiometabolic improvements documented beyond body weight provide a multi-marker framework for research outcome assessment.
Vietnam Peptides’ Retatrutide 20mg is available with same-day shipping from its Da Nang branch — making the research compound directly accessible to Danang expats without international sourcing logistics. Product: Retatrutide 20mg — Vietnam Peptides. Structured research frameworks are available through the Fat Loss Peptide Research Plan and the Knowledge Hub.
Remaining Research Questions
The Phase II data leaves several important research questions for Phase III to address. The most important is whether the 24.2% Phase II outcome will hold — or improve — in the larger, longer Phase III population. Phase III trials typically refine dose escalation, extend duration, and enroll more diverse populations, all of which can affect outcomes in either direction.
The lean mass preservation question is partially answered but not definitive: whether optimized protocols (integrating resistance training, potentially adjusted dose escalation, or complementary peptides) can improve the fat-to-lean mass loss ratio beyond what the Phase II trial achieved without exercise standardization. The cardiovascular outcomes trial (similar to tirzepatide’s SURPASS-CVOT) has not yet been completed for retatrutide at time of writing. And the long-term (beyond 48 weeks) weight maintenance dynamics of retatrutide — whether outcomes are maintained, improve, or require continued treatment — remain to be definitively established at Phase III scale.
Key Statistics
📈 NEJM 2023 Phase II Key Numbers
| Metric | Value | Dose |
|---|---|---|
| Body weight reduction | 24.2% | 12mg, 48 weeks |
| Triglyceride reduction | ~41% | 12mg |
| Fasting glucose reduction | −20.1 mg/dL | 12mg |
| Systolic BP reduction | −7.9 mmHg | 12mg |
| Trial participants | 338 | Phase II |
Frequently Asked Questions
The landmark finding was 24.2% mean body weight reduction at the highest dose (12mg) over 48 weeks — the highest published Phase II fat loss outcome for any incretin-class compound. The trial also documented significant improvements in triglycerides, fasting glucose, blood pressure, and insulin markers, confirming comprehensive cardiometabolic benefit alongside weight reduction.
338 adults were enrolled in the Phase II trial (NCT04881760). Participants had BMI ≥30 or ≥27 with weight-related comorbidities, and were randomized to weekly retatrutide doses (1, 4, 8, or 12mg) or placebo for 48 weeks. This is a standard Phase II sample size — large enough to establish efficacy signals and dose-response relationships, smaller than Phase III populations needed for definitive efficacy confirmation.
Direct comparison is complicated by different trial phases, population sizes, and durations. Tirzepatide’s SURMOUNT-1 Phase III showed 22.5% at 72 weeks with 2,539 participants; reta’s Phase II showed 24.2% at 48 weeks with 338 participants. The Phase II-to-Phase III comparison is not apples-to-apples, but the signal is directionally favorable for reta. Phase III data will provide the definitive comparison basis.
As of the most recent available information, retatrutide (LY3437943) by Eli Lilly has advanced to Phase III clinical trials following the successful Phase II outcomes. Phase III trials are conducting larger-scale, longer-duration efficacy and safety evaluation. Da Nang expat researchers can track Phase III progress through ClinicalTrials.gov (NCT identifier: NCT04881760 for Phase II; Phase III registrations available separately).
The most common adverse events were gastrointestinal: nausea (42–62% at higher doses), vomiting (13–27%), diarrhea, and decreased appetite. These were predominantly mild to moderate, occurred most frequently during dose escalation, and generally resolved at stable doses. The safety profile was consistent with GLP-1-class compound class effects.
Yes. Vietnam Peptides supplies research-grade Retatrutide 20mg from its Da Nang branch for laboratory research use, providing Danang researchers with access to study the compound consistent with its Phase II evidence base. All products are for research purposes only.
24.2% body weight reduction in Phase II is historically significant because it exceeds the outcomes of all prior incretin compounds at comparable Phase II stages, approaches the magnitude of bariatric surgical outcomes (typically 20–30%), and is achieved through a purely pharmacological mechanism at only 48 weeks. It validates the hypothesis that triple-receptor incretin agonism provides meaningfully superior outcomes compared to dual agonism — a finding that is reshaping the metabolic pharmacology research landscape globally.
Beyond body weight: ~41% triglyceride reduction, −20.1 mg/dL fasting glucose, −7.9 mmHg systolic blood pressure, improved HbA1c in elevated-baseline subgroups, and modest HDL cholesterol increases. These comprehensive cardiometabolic improvements across multiple biomarkers position retatrutide research as relevant to the full metabolic health and longevity optimization landscape — not only body composition.
Related Products
≥99% HPLC purity. BAC water included. Same-day shipping from Da Nang branch.
Phase III evidence base. The dual-agonist reference compound for incretin comparison research. Available in Danang.
GH-axis visceral fat research — distinct mechanism from triple incretin; complementary for comprehensive metabolic protocols.
Fat Loss Peptide Research Plan
Research frameworks integrating retatrutide with complementary metabolic compounds — structured for Da Nang expat researchers following the evidence-based frontier.
Explore the Fat Loss Research Plan →Scientific References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023. PMID: 37366315
- Coskun T, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist. Cell Metabolism. 2022. PMID: 35839743
- Jastreboff AM, et al. Tirzepatide for Obesity (SURMOUNT-1). New England Journal of Medicine. 2022. PMID: 35658024
- Day JW, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nature Chemical Biology. 2009. PMID: 19597507
- Holst JJ. The incretin system in healthy humans. Metabolism. 2019. PMID: 31082441
- Pi-Sunyer X, et al. Liraglutide in Weight Management (SCALE Obesity). New England Journal of Medicine. 2015. PMID: 26132939
- Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist. Cardiovascular Diabetology. 2022. PMID: 36064667
- ClinicalTrials.gov. A Study of LY3437943 in Participants With Obesity. NCT04881760. 2023.
Related Entities: LY3437943, Eli Lilly, NEJM 2023, NCT04881760, glucagon receptor, GLP-1, GIP, 24.2% weight reduction, cardiometabolic outcomes, Da Nang research community, Vietnam Peptides
Search Intent: Research-Oriented / Industry News
Key Questions Answered: What did the 2023 NEJM retatrutide trial find? How many participants? What were side effects? How does 24.2% compare to tirzepatide? Where to access reta in Da Nang based on Phase II data?
Evidence Sources: NEJM 2023 Jastreboff (primary), Cell Metabolism 2022 Coskun, Nature Chemical Biology 2009 Day, NEJM 2022 SURMOUNT-1
Relevant User Profiles: Expert researchers in Da Nang tracking incretin trial data, longevity scientists in Danang following metabolic pharmacology, advanced biohackers reading Phase II literature
Knowledge Graph Connections: Retatrutide Phase II → NEJM 2023 → 24.2% weight reduction → glucagon thermogenesis → cardiometabolic outcomes → Da Nang research access → Vietnam Peptides Danang
Post Metadata — User Level: Expert | Audience: Longevity Enthusiasts / Expats in Vietnam | Category: Research Updates | Location: Da Nang / Danang | Primary Keywords: retatrutide Phase II Da Nang, NEJM 2023 retatrutide Danang | Secondary: LY3437943 research update Da Nang, reta Phase II Vietnam expat, triple incretin 24% weight loss Danang